This is an I-Heart podcast.

Guaranteed Human.

You are listening to the Tudor Dixon podcast, and today we are talking about

Ozempic.

You guys have all heard all kinds of stories about OZempic.

Some of you probably have used it.

Some of you may not know the whole history of what OZempic is or how it even works.

And that's why we decided to bring

the author of the new book Off the Scales, the Inside Story of Ozempic and the Race to Cure Obesity.

Amy Donnellin, thank you so much, Amy, for being on today. It's really great to be here.

Thank you so much, Shooter. Absolutely. So first of all, as I was reading through this,

I didn't even, I guess we don't understand how drugs come to be and there was a lot of

years and years of work on this. It was obviously for, I think many of us know it was for diabetes,

but then they started to see all of these other things.

It has kind of set off a whole line of questions from all different industries.

But tell us a little bit about how you got into figuring out how Ozempic came to be.

Well, it's funny, actually, so I cover pharmaceuticals for Reuters, which is the news agency.

So I cover Nova Nordisk, which is the company that makes Ozenthic and now Wegevy, which is the obesity drug.

And it was actually during the pandemic that I was asked to write a piece about what was being called at the time virus vices.

So this was basically the idea that people were sitting at home,

drinking, smoking, doing all sorts of things

that were really, really bad for their health.

...